Last Modified: November 13, 2003
As our understanding of the underlying molecular abnormalities and pathogenesis of various cancers continues to grow, while simultaneously new chemotherapeutic agents and new biological "targeted agents" continue to proliferate, the ability of the clinical oncologist (i.e., those not focused on research) to maintain an awareness and understanding of the vast array of therapeutic choices that is available is, at the very least, "daunting". The ASCO 2003 meeting featured over 3,600 abstracts covering preclinical and clinical developments for currently commercialized agents, as well as new agents not yet approved, across all tumor-types. The number of anticancer agents in clinical trials is estimated to exceed 400. There are limited opportunities for clinicians to hear key opinion leaders, specializing in all major oncology specialties, present cutting edge clinical information. Professional forums, such as ASCO and the Chemotherapy Foundation, provide rare opportunities for oncology professionals to hear, first-hand from investigators, the latest data and interpretation for cancer treatments spanning all major tumor-types.
The Chemotherapy Foundation Symposium (CFS) provides "coverage of emerging advances in the treatment of neoplastic diseases" and affords the opportunity "to learn about the new drugs, new modalities, current trials, new procedures and evolving developments in biotherapies". OncoLink will report on key presentations to enhance the learning opportunities of the oncology professional. This module will report on clinical updates and new approaches under investigation for the treatment of ovarian cancer and head and neck cancer, and adjuvant therapy for breast cancer.
After completing this program, participants will be able to:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). The American Academy of CME, Inc., is accredited by the ACCME to provide continuing medical education for physicians.
The American Academy of CME, Inc., designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
This educational activity has been approved through November 2004.
After reading all of the articles within this module you will be able to download the Program Evaluation (a PDF file), which you can print out. In order to receive your CME certificate, please complete the form and mail or fax as shown on the form.
Certificates will be mailed 6 to 8 weeks following receipt of your evaluation.
|First Line Therapy Of Ovarian Cancer: What Next?|
|Tate Thigpen, M.D.|
|Paclitaxel And Platinum Versus Platinum-Based Chemotherapy In Relapsed Ovarian Cancer: Icon 4|
|Jonathan A. Ledermann, M.D.|
|Update On GOG Studies In Ovarian Cancer|
|Robert F. Ozols, M.D.|
|Duration Of Therapy For Ovarian Cancer: How Long Is Enough?|
|David Spriggs, M.D.|
|Head And Neck Cancer|
|EGFR Inhibitors In Head And Neck Cancer|
|Merrill S. Kies, M.D.|
|Motexafin Gadolinium And Concurrent Chemoradiation In Head And Neck Cancer|
|David M. Brizel, M.D.|
|Breast Cancer Adjuvant Therapy: Trailbazers And Milestones|
|Cox 2/Hormonal Approaches For Treatment And Prevention Of Breast Cancer|
|Paul E. Goss, M.D., Ph.D.|
|Adjuvant Hormonal Therapy In Premenopausal Women|
|Gini F. Fleming, M.D.|
|Vaccines For Breast Cancer: Real Challenge Or Reality?|
|Nuhad K. Ibrahim, M.D.|
|Adding Carboplatin To Herceptin/Taxanes In Her2+ Breast Cancer: An Update|
|Nicholas J. Robert, M.D.|
May 29, 2014 - The American Society of Clinical Oncology is updating its guidelines on adjuvant endocrine therapy to recommend tamoxifen for up to 10 years for women with nonmetastatic hormone receptor-positive breast cancer. This updated clinical practice guideline was published online May 26 in the Journal of Clinical Oncology.
May 29, 2014
Mar 2, 2010
Jan 14, 2011